A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

被引：25
|
作者：
Thondam, S. K. [1 ]
Cuthbertson, D. J. [1 ]
Aditya, B. S. [1 ]
MacFarlane, I. A. [1 ]
Wilding, J. P. [1 ]
Daousi, C. [1 ]
机构：
[1] Univ Liverpool, Dept Obes & Endocrinol, Aintree Univ Hosp NHS Fdn Trust Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
CLINICAL ENDOCRINOLOGY | 2012年 / 77卷 / 04期
关键词：
FOOD-INTAKE; WEIGHT; HUMANS; DAMAGE;
D O I：
10.1111/j.1365-2265.2012.04368.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [21] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [22] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
    Lassen, Mats C. H.
    Johansen, Niklas Dyrby
    Modin, Daniel
    Catarig, Andrei-Mircea
    Vistisen, Bodil Kjeldgaard
    Amadid, Hanan
    Zimmermann, Esther
    Gislason, Gunnar
    Biering-Sorensen, Tor
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5239 - 5250
  • [23] Danuglipron Glucagon-like peptide 1 receptor agonist Treatment of type 2 diabetes Treatment of obesity
    Sperry, Alexander J.
    Hardy, Jennifer
    Goldfaden, Rebecca F.
    Hurst, Amber
    Ashchi, Andrea
    Sutton, David
    Sheikh-Ali, Mae
    Huston, Jessica
    Choksi, Rushab
    DRUGS OF THE FUTURE, 2022, 47 (06) : 407 - 418
  • [24] Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
    Sreenivasan, Chithra
    Parikh, Aneri
    Francis, Aida J.
    Kanthajan, Tatchaya
    Pandey, Manorama
    Alqassab, Osamah
    Nath, Tuheen Sankar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [25] On the treatment of diabetes mellitus with glucagon-like peptide-1
    Holst, JJ
    Deacon, C
    Toft-Nielsen, MB
    Bjerre-Knudsen, L
    VIP, PACAP, AND RELATED PEPTIDES: THIRD INTERNATIONAL SYMPOSIUM, 1998, 865 : 336 - 343
  • [26] Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?
    Elder, Mary J.
    Ashjian, Emily J.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (02) : 418 - 428
  • [27] Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
    Anne B. Brooks
    Jakob Langer
    Tommi Tervonen
    Mads Peter Hemmingsen
    Kosei Eguchi
    Elizabeth D. Bacci
    Diabetes Therapy, 2020, 11 : 2443 - 2446
  • [28] Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
    Williams, David M.
    Atkinson, Michael
    Evans, Marc
    STROKE, 2023, 54 (05) : 1441 - 1451
  • [29] Response to "Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment"
    Brooks, Anne B.
    Langer, Jakob
    Tervonen, Tommi
    Peter Hemmingsen, Mads
    Eguchi, Kosei
    Bacci, Elizabeth D.
    DIABETES THERAPY, 2020, 11 (10) : 2443 - 2446
  • [30] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
    Ja'arah, Daria
    Al Zoubi, Mazhar Salim
    Abdelhady, Gamal
    Rabi, Firas
    Tambuwala, Murtaza M.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2021, 14
12345